DermTech Discontinus Optional TERT Add-On Assay For DermTech Melanoma Test
Portfolio Pulse from Benzinga Newsdesk
DermTech has decided to discontinue the optional TERT promoter mutation testing add-on for its melanoma test after the Trust 2 Study showed that the foundational gene expression assay alone has a negative predictive value (NPV) of 99.7%. The study indicated that adding TERT mutation testing did not significantly improve the test's sensitivity, NPV, or positive predictive value (PPV).
January 16, 2024 | 1:30 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
DermTech's discontinuation of the TERT add-on assay for its melanoma test may streamline operations and reinforce confidence in the foundational assay's accuracy.
While the discontinuation of the TERT add-on assay indicates confidence in the foundational test's effectiveness, it may not have a significant short-term impact on the stock price. Investors may view this as a neutral move since it doesn't drastically alter the company's product offering but rather streamlines it.
CONFIDENCE 75
IMPORTANCE 60
RELEVANCE 80